Professor Wu Jing: Ambiguous Guideline Recommendations Harm Patient Care

Professor Wu Jing, Party Secretary of the School of Pharmaceutical Science and Technology, Tianjin University, published a viewpoint article titled “Ambiguous Guideline Recommendations Harm Patient Care” in The BMJ .

The article argues that guidelines should help clinicians and patients make better decisions, but too often they do the opposite. Providing recommendations that are vague, outdated, or inactionable can harm patients by causing confusion and misunderstanding, delaying care, and eroding trust in evidence-based medicine. If recommendations fail to guide actionable decisions at the point of care, they are not just useless-they are harmful.

Recommendations often default to broad, non-committal language: “consider,” “offer support,” or “individualize” treatment without specifying priorities, sequences, or stopping rules. This vagueness leaves clinicians guessing, resulting in patients being underserved and inefficiency in healthcare systems. Instead, recommendations should clearly define eligibility criteria, initial steps, monitoring protocols, escalation pathways, and exit strategies. Without this, guidelines lack utility, and key insights are buried or lost, undermining credibility.

Timeliness and consistency are equally critical. Static guidelines quickly become obsolete, yet many lack mechanisms for ongoing updates. New evidence and regulatory approvals have reshaped therapeutic landscapes, but guidelines in some countries remain years out of date. Discordance among guidelines further compounds the problem: confusion arises when conflicting recommendations are issued without explaining divergences in evidence interpretation, outcome priorities, or resource assumptions. These inconsistencies risk fragmenting care, deepening inequities, and eroding public trust.

To address these challenges, the authors call for guideline development to transition towards a living, adaptive model rooted in timeliness, usability, and consistency. This includes adopting continuous evidence surveillance systems to detect new evidence and regulatory approvals in real time, embedding practical decision aids such as flowcharts, algorithms for initiating or discontinuing pharmacotherapy, and criteria for combination treatment strategies directly into recommendations, and using evidence-to-decision frameworks that integrate certainty of evidence, benefits and harms, patient values and preferences, and resource considerations to transform vague advice into concrete, patient-centred pathways. Guideline developers should also clearly justify their recommendations by explicitly describing how evidence and other factors were weighed, particularly when issuing strong recommendations based on low-certainty evidence. By embracing actionable, timely, and harmonious recommendations, guidelines can be restored as trusted tools for better care.

The first author of the article is Professor Wu Jing. The co-authors include Professor Gao Ya (Shandong University), Dr. Liu Ming, and Assistant Professor Yao Liang (Nanyang Technological University, Singapore).

For the full article, please visit: https://doi.org/10.1136/bmj-2026-348420

By School of Pharmaceutical Science and Technology

Editor: Sun Xiaofang